102.61
price up icon0.37%   0.38
after-market アフターアワーズ: 102.61
loading
前日終値:
$102.23
開ける:
$101.83
24時間の取引高:
27.05M
Relative Volume:
2.50
時価総額:
$177.55B
収益:
$46.59B
当期純損益:
$5.41B
株価収益率:
33.17
EPS:
3.0938
ネットキャッシュフロー:
$7.38B
1週間 パフォーマンス:
+0.65%
1か月 パフォーマンス:
-8.94%
6か月 パフォーマンス:
-5.42%
1年 パフォーマンス:
-23.75%
1日の値動き範囲:
Value
$101.50
$103.19
1週間の範囲:
Value
$100.33
$104.44
52週間の値動き範囲:
Value
$81.97
$137.49

Abbott Laboratories Stock (ABT) Company Profile

Name
名前
Abbott Laboratories
Name
セクター
Healthcare (1065)
Name
電話
(224) 667-6100
Name
住所
100 ABBOTT PARK ROAD, ABBOTT PARK, IL
Name
職員
115,000
Name
Twitter
@AbbottNews
Name
次回の収益日
2026-10-21
Name
最新のSEC提出書
Name
ABT's Discussions on Twitter

Compare ABT vs MDT, SYK, BSX, EW

株式 価格 時価総額 収益 当期純利益 現金流量 EPS
ABT icon
ABT
Abbott Laboratories
102.61 176.41B 46.59B 5.41B 7.38B 3.0938
MDT icon
MDT
Medtronic Plc
92.13 116.35B 36.36B 4.84B 5.43B 3.7261
SYK icon
SYK
Stryker Corp
275.12 105.70B 25.27B 3.34B 4.57B 8.6334
BSX icon
BSX
Boston Scientific Corp
43.34 62.29B 20.62B 3.56B 3.48B 2.3847
EW icon
EW
Edwards Lifesciences Corp
88.26 48.63B 6.30B 1.07B 1.09B 1.8406

Abbott Laboratories Stock (ABT) Upgrades & Downgrades

日付 アクション アナリスト 評価の変更
2026-04-22 ダウングレード Daiwa Securities Outperform → Neutral
2025-10-10 開始されました The Benchmark Company Buy
2025-07-18 アップグレード Jefferies Hold → Buy
2025-06-16 開始されました Leerink Partners Market Perform
2024-10-08 開始されました Oppenheimer Outperform
2024-09-19 開始されました Piper Sandler Overweight
2024-07-30 ダウングレード Edward Jones Buy → Hold
2024-05-30 開始されました Goldman Buy
2023-07-21 アップグレード Wolfe Research Underperform → Peer Perform
2023-05-30 ダウングレード Morgan Stanley Overweight → Equal-Weight
2023-04-20 繰り返されました Barclays Overweight
2023-04-20 繰り返されました Bernstein Outperform
2023-04-20 繰り返されました JP Morgan Overweight
2023-04-20 繰り返されました Raymond James Outperform
2023-04-20 繰り返されました UBS Buy
2023-04-20 繰り返されました Wolfe Research Underperform
2023-03-29 開始されました UBS Buy
2022-10-26 開始されました Mizuho Neutral
2022-10-18 開始されました Barclays Overweight
2022-10-12 開始されました Jefferies Hold
2022-07-06 開始されました Wolfe Research Underperform
2022-03-02 再開されました BofA Securities Buy
2022-01-27 繰り返されました Credit Suisse Outperform
2022-01-27 繰り返されました Morgan Stanley Overweight
2022-01-27 繰り返されました Raymond James Outperform
2022-01-27 繰り返されました UBS Buy
2021-12-10 開始されました RBC Capital Mkts Outperform
2021-10-27 アップグレード Atlantic Equities Neutral → Overweight
2021-10-14 開始されました Redburn Neutral
2021-05-25 開始されました Barclays Overweight
2021-04-15 開始されました Atlantic Equities Neutral
2021-01-28 アップグレード BTIG Research Neutral → Buy
2020-09-11 開始されました Wolfe Research Outperform
2020-06-01 ダウングレード Goldman Neutral → Sell
2020-03-05 開始されました Citigroup Buy
2020-02-13 開始されました Goldman Neutral
2020-02-06 再開されました BTIG Research Neutral
2020-01-02 ダウングレード Guggenheim Buy → Neutral
2019-06-13 繰り返されました BofA/Merrill Buy
2019-02-07 繰り返されました BofA/Merrill Buy
2019-01-02 ダウングレード Citigroup Neutral → Sell
2018-11-30 アップグレード Goldman Neutral → Buy
2018-10-16 開始されました Barclays Overweight
2018-06-27 開始されました Bernstein Outperform
2018-01-30 繰り返されました Citigroup Neutral
2018-01-25 繰り返されました Stifel Buy
2018-01-25 アップグレード William Blair Mkt Perform → Outperform
2018-01-03 開始されました Evercore ISI Outperform
2018-01-02 アップグレード JP Morgan Neutral → Overweight
2018-01-02 アップグレード Morgan Stanley Equal-Weight → Overweight
2017-10-19 繰り返されました RBC Capital Mkts Outperform
2017-10-19 繰り返されました Stifel Buy
すべてを表示

Abbott Laboratories (ABT) 最新ニュース

pulisher
Sep 13, 2026

Two Medical Device Dividend Giants, One Better Buy: Medtronic vs. Abbott - AOL.com

Sep 13, 2026
pulisher
Sep 12, 2026

Abbott Laboratories Stock (ABT) Opinions on Analyst Buy Rating Reiteration - Quiver Quantitative

Sep 12, 2026
pulisher
Sep 12, 2026

Is Abbott Laboratories (ABT) Reasonably Priced After Its FDA Win? - simplywall.st

Sep 12, 2026
pulisher
Sep 11, 2026

Abbott Laboratories stock underperforms Friday when compared to competitors - MarketWatch

Sep 11, 2026
pulisher
Sep 11, 2026

Abbott Laboratories stock gains as Citi lifts price target and guidance stays firm - ad-hoc-news.de

Sep 11, 2026
pulisher
Sep 11, 2026

Abbott Cancer Diagnostics Targets Prospective Studies for MCED Test a Year After Launch - GenomeWeb

Sep 11, 2026
pulisher
Sep 11, 2026

Investors Heavily Search Abbott Laboratories (ABT): Here is What You Need to Know - Yahoo Finance

Sep 11, 2026
pulisher
Sep 11, 2026

The Zacks Analyst Blog Highlights Goldman Sachs, RTX, Abbott, NLI and Precipio - Yahoo Finance

Sep 11, 2026
pulisher
Sep 11, 2026

Abbott Laboratories Share Price Today (ABT) | Live Chart, News & Stock Market - TechGraph

Sep 11, 2026
pulisher
Sep 10, 2026

Abbott Laboratories stock heads into the open after a 0.4% dip - ad-hoc-news.de

Sep 10, 2026
pulisher
Sep 10, 2026

Abbott Laboratories stock underperforms Thursday when compared to competitors - MarketWatch

Sep 10, 2026
pulisher
Sep 10, 2026

Top Research Reports for Goldman Sachs, RTX & Abbott - finance.yahoo.com

Sep 10, 2026
pulisher
Sep 10, 2026

Abbott Spinal Cord Stimulator Explant Surgery Required After Device Failure: Lawsuit - AboutLawsuits.com

Sep 10, 2026
pulisher
Sep 10, 2026

Abbott Laboratories stock falls after FDA approval - ad-hoc-news.de

Sep 10, 2026
pulisher
Sep 10, 2026

Abbott Laboratories stock before the bell falls 2.6 percent - ad-hoc-news.de

Sep 10, 2026
pulisher
Sep 09, 2026

Abbott Laboratories (ABT) Secured FDA Approval, Is It Still 11% Below Fair Value? - simplywall.st

Sep 09, 2026
pulisher
Sep 09, 2026

Abbott Wins FDA Clearance for Dual-Energy AFib Catheter - finance.biggo.com

Sep 09, 2026
pulisher
Sep 09, 2026

Abbott partners with Sengkang General Hospital to advance early detection of muscle loss in Singapore - BioSpectrum Asia

Sep 09, 2026
pulisher
Sep 09, 2026

Abbott Is Selling Sterility as a Feature. In Liquid Formula It Is Already the Rule. - marlerblog.com

Sep 09, 2026
pulisher
Sep 09, 2026

Abbott Receives FDA Nod for TactiFlex Duo: Stock to Gain? - Yahoo Finance

Sep 09, 2026
pulisher
Sep 09, 2026

Abbott garners FDA nod for its TactiFlex catheter to treat AFib - Fierce Biotech

Sep 09, 2026
pulisher
Sep 09, 2026

Abbott’s dual ablation catheter lands FDA approval - Yahoo Finance

Sep 09, 2026
pulisher
Sep 09, 2026

Wells Fargo Maintains Abbott Laboratories(ABT.US) With Buy Rating, Maintains Target Price $112 - Moomoo

Sep 09, 2026
pulisher
Sep 09, 2026

Abbott Laboratories stock gains after FDA approval and strong guidance - ad-hoc-news.de

Sep 09, 2026
pulisher
Sep 08, 2026

Abbott Laboratories stock heads into the open after a modest loss - ad-hoc-news.de

Sep 08, 2026
pulisher
Sep 08, 2026

Here's Why Abbott (ABT) Fell More Than Broader Market - finance.yahoo.com

Sep 08, 2026
pulisher
Sep 08, 2026

Abbott Laboratories stock underperforms Tuesday when compared to competitors - MarketWatch

Sep 08, 2026
pulisher
Sep 08, 2026

1 No-Brainer ETF I'm Loading Up on in 2026 and Beyond - The Motley Fool

Sep 08, 2026
pulisher
Sep 08, 2026

FDA approves new Abbott catheter capable of PFA and radiofrequency ablation - Cardiovascular Business

Sep 08, 2026
pulisher
Sep 08, 2026

Abbott wins FDA approval for dual-energy ablation catheter - MedTech Dive

Sep 08, 2026
pulisher
Sep 08, 2026

Abbott receives FDA approval for AFib ablation catheter - grafa.com

Sep 08, 2026
pulisher
Sep 08, 2026

Abbott Laboratories (ABT) Won FDA Approval For Its TactiFlex Duo Catheter - simplywall.st

Sep 08, 2026
pulisher
Sep 08, 2026

Abbott scores another win at UPC with SiBio preliminary injunction - IAM Patent

Sep 08, 2026
pulisher
Sep 08, 2026

Abbott receives FDA approval for dual-energy heart ablation catheter By Investing.com - Investing.com Canada

Sep 08, 2026
pulisher
Sep 08, 2026

Abbott wins FDA nod for cardiac ablation catheter (ABT:NYSE) - Seeking Alpha

Sep 08, 2026
pulisher
Sep 08, 2026

The FDA Clears an Abbott Product - marketscreener.com

Sep 08, 2026
pulisher
Sep 08, 2026

10.5 million people in the U.S. live with hearts that beat too fast, too slow or irregularly. Abbott gets FDA approval. - Stock Titan

Sep 08, 2026
pulisher
Sep 08, 2026

Abbott Laboratories stock holds firm after July earnings - AD HOC NEWS

Sep 08, 2026
pulisher
Sep 07, 2026

Abbott Laboratories (NYSE:ABT): Can Heart Research Lift Its Next Move? - Kalkine Media

Sep 07, 2026
pulisher
Sep 07, 2026

Abbott Blocks Rival's Glucose Monitor Sales In Europe - Law360

Sep 07, 2026
pulisher
Sep 07, 2026

Abbott Laboratories stock holds valuation premium amid steady earnings - ad-hoc-news.de

Sep 07, 2026
pulisher
Sep 07, 2026

Abbott Laboratories (ABT) Stock Analysis: Analyst Consensus Reveals a 10.96% Upside Potential - DirectorsTalk Interviews

Sep 07, 2026
pulisher
Sep 06, 2026

Abbott Stock And Other Defensive Dividend Picks For Uncertain Markets - simplywall.st

Sep 06, 2026
pulisher
Sep 06, 2026

Abbott Laboratories stock holds near $108 after strong Q2 - AD HOC NEWS

Sep 06, 2026
pulisher
Sep 06, 2026

Abbott Laboratories Profile: Recipients - opensecrets.org

Sep 06, 2026
pulisher
Sep 05, 2026

Abbott Laboratories (ABT) Q2 2026 Earnings Call Transcript - Fortune

Sep 05, 2026
pulisher
Sep 05, 2026

How New Diabetes, Cardiac, Nutrition and Cancer Tools At Abbott Laboratories (ABT) Have Changed Its Investment Story - simplywall.st

Sep 05, 2026
pulisher
Sep 04, 2026

Abbott CFO Philip P. Boudreau Retains 70,784 Shares After Forfeiting 388 Shares at $110.36 Each - Kalkine Media

Sep 04, 2026
pulisher
Sep 04, 2026

Ferguson Wellman Capital Management Inc. Sells 136,385 Shares of Abbott Laboratories $ABT - InsuranceNewsNet

Sep 04, 2026
pulisher
Sep 04, 2026

Renal Denervation Market Size, Share & Trends Analysis - GlobeNewswire Inc.

Sep 04, 2026
pulisher
Sep 04, 2026

US companies face rise in cyber attacks - Reuters

Sep 04, 2026

Abbott Laboratories (ABT) 財務データ

収益

loading

当期純利益

loading

現金流量

loading

EPS

loading
MDT MDT
$92.13
price down icon 0.69%
SYK SYK
$275.12
price down icon 1.79%
BSX BSX
$43.34
price down icon 0.48%
EW EW
$88.26
price up icon 0.01%
$89.35
price up icon 1.61%
大文字化:     |  ボリューム (24 時間):